Detalles de la búsqueda
1.
Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience.
Transpl Infect Dis
; 23(3): e13522, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33217163
2.
Primary sclerosing cholangitis as an independent risk factor for cytomegalovirus infection after liver transplant.
Transpl Infect Dis
; 23(3): e13553, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33368987
3.
Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry.
J Viral Hepat
; 27(7): 690-698, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32096310
4.
HLA class II donor specific antibodies are associated with graft cirrhosis after liver transplant independent of the mean fluorescence intensity level.
BMC Gastroenterol
; 20(1): 288, 2020 Aug 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32854625
5.
The Effect of Immunosuppression on Coagulation After Liver Transplantation.
Liver Transpl
; 25(7): 1054-1065, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31021493
6.
Improving the vaccination status of liver transplant patients: Effectiveness of personally addressing patients and written recommendations to family physicians after 3 years.
Transpl Infect Dis
; 21(5): e13140, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31271692
7.
Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
Transpl Infect Dis
; 21(5): e13146, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31306562
8.
The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
Transpl Infect Dis
; 20(1)2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29111569
9.
Immunosuppression with mTOR inhibitors prevents the development of donor-specific antibodies after liver transplant.
Clin Transplant
; 31(6)2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28345271
10.
Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.
Transpl Int
; 30(3): 243-255, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28012215
11.
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.
Transpl Infect Dis
; 19(3)2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28295849
12.
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
Gut
; 65(11): 1861-1870, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27605539
13.
Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis.
Liver Transpl
; 22(1): 42-52, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26438008
14.
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Liver Transpl
; 22(4): 446-58, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26890629
15.
Selection and use of immunosuppressive therapies after liver transplantation: current German practice.
Clin Transplant
; 30(5): 487-501, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26855333
16.
Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.
Ann Hepatol
; 15(4): 512-23, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27236150
17.
TRAIL expression levels in human hepatocellular carcinoma have implications for tumor growth, recurrence and survival.
Int J Cancer
; 136(4): E154-60, 2015 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25123818
18.
Transplanting HCV-Infected Kidneys into Uninfected Recipients.
N Engl J Med
; 377(11): 1103-4, 2017 09 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28902583
19.
(Cleaved) CK18 serum and tissue expression levels differentiate acute HCV reinfection from acute rejection in liver allografts.
Liver Int
; 35(3): 905-13, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24750688
20.
Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.
Digestion
; 91(4): 326-33, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25999053